News stories about Ra Pharmaceuticals (NASDAQ:RARX) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ra Pharmaceuticals earned a news impact score of 0.11 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.4132759101521 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

RARX has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. BMO Capital Markets reaffirmed an “outperform” rating and set a $34.00 price objective (up previously from $31.00) on shares of Ra Pharmaceuticals in a research report on Monday, December 4th. Jefferies Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Ra Pharmaceuticals in a research report on Thursday, September 28th. Royal Bank of Canada reiterated a “buy” rating and issued a $18.00 target price on shares of Ra Pharmaceuticals in a report on Tuesday, December 5th. Finally, Credit Suisse Group increased their target price on Ra Pharmaceuticals from $19.00 to $23.00 and gave the stock an “outperform” rating in a report on Friday, November 10th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Ra Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $21.90.

Shares of Ra Pharmaceuticals (NASDAQ:RARX) traded down $0.12 on Friday, hitting $8.49. The company had a trading volume of 65,723 shares, compared to its average volume of 172,785. Ra Pharmaceuticals has a 12 month low of $7.15 and a 12 month high of $27.84. The company has a market cap of $194.82, a PE ratio of -3.44 and a beta of 6.29.

Ra Pharmaceuticals (NASDAQ:RARX) last issued its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.06). sell-side analysts anticipate that Ra Pharmaceuticals will post -2.46 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Insider Buying and Selling by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with's FREE daily email newsletter.